Prevnar-13

BIOLOGICAL3 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Ludwig Institute for Cancer Research, VA Eastern Colorado Health Care System

Conditions

HIV InfectionsHIV-1-infectionHIV/AIDSHuman Immunodeficiency VirusMultiple Myeloma

Early Phase 1

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Active, not recruitingNCT03729778

VA Eastern Colorado Health Care SystemHIV-1-infection, HIV/AIDS, HIV Infections +1

Start: 2017-01-18End: 2028-01-01Target: 100Updated: 2026-07-29

Phase 1

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

TerminatedNCT02716805

Ludwig Institute for Cancer ResearchMultiple Myeloma

Start: 2016-12-13End: 2018-02-16Updated: 2022-10-12

Phase 2

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

CompletedNCT01349569

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMultiple Myeloma

Start: 2012-01-31End: 2016-10-31Updated: 2019-01-15

Related Papers

Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

Blood2020-11-053 citations

Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) + peripheral blood lymphocyte (PBL) reinfusion.

Journal of Clinical Oncology2017-05-203 citations

Allogeneic myeloma GVAX with lenalidomide in near complete remission to enhance progression free survival.

Journal of Clinical Oncology2015-05-205 citations